Affordable Access

Publisher Website

Renin–angiotensin system inhibition is not associated with increased sudden cardiac death, cardiovascular mortality or all-cause mortality in patients with aortic stenosis

Authors
Journal
International Journal of Cardiology
0167-5273
Publisher
Elsevier
Publication Date
Identifiers
DOI: 10.1016/j.ijcard.2014.06.013
Keywords
  • Aortic Stenosis
  • Renin–Angiotensin System Inhibition
  • Angiotensin-Converting Enzyme Inhibitor
  • Angiotensin Receptor Blocker
  • Mortality
  • Hypertension
Disciplines
  • Biology
  • Medicine
  • Pharmacology

Abstract

Abstract Background Renin–angiotensin system inhibition (RASI) is frequently avoided in aortic stenosis (AS) patients because of fear of hypotension. We evaluated if RASI with angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) increased mortality in patients with mild to moderate AS. Methods All patients (n=1873) from the Simvastatin and Ezetimibe in Aortic Stenosis study: asymptomatic patients with AS and preserved left ventricular (LV) ejection fraction were included. Risks of sudden cardiac death (SCD), cardiovascular death and all-cause mortality according to RASI treatment were analyzed by multivariable time-varying Cox models and propensity score matched analyses. Results 769 (41%) patients received RASI. During a median follow-up of 4.3±0.9years, 678 patients were categorized as having severe AS, 545 underwent aortic valve replacement, 40 SCDs, 103 cardiovascular and 205 all-cause deaths occurred. RASI was not associated with SCD (HR: 1.19 [95%CI: 0.50–2.83], p=0.694), cardiovascular (HR: 1.05 [95%CI: 0.62–1.77], p=0.854) or all-cause mortality (HR: 0.81 [95%CI: 0.55–1.20], p=0.281). This was confirmed in propensity matched analysis (all p>0.05). In separate analyses, RASI was associated with larger reduction in systolic blood pressure (p=0.001) and less progression of LV mass (p=0.040). Conclusions RASI was not associated with SCD, cardiovascular or all-cause mortality in asymptomatic AS patients. However, RASI was associated with a potentially beneficial decrease in blood pressure and reduced LV mass progression.

There are no comments yet on this publication. Be the first to share your thoughts.